GWD,
Jack Rayfield would probably be in a better position to answer your question.
However, I will say this. LOR is a very intelligent and resourceful individual. In the past, many people have found his/her posts quite distasteful (referring to a certain other discussion forum). However, IMHO he/she has always been honest in his/her posts and has told it as it is. Now, from my limited experience, I can honestly say that he/she does his/her homework! In other words, he/she knows what he's/she's talking about.
Now, looking at his/her post
1) Great product but no investor confidence evident over the past several months,
2) No disclosure on the part of PYNG of the actual WR test results
[ ESTIMATED by PYNG to be concluded by last ""AUGUST"" either because the report has not yet been issued by WR [ probable ] ""OR"" because PYNG does not wish to release same [ not so probable in my opinion ]
3) Evidence that PYNG has three "FDA approved" competitors for the intraosseous infusion market and informal reports that none of the devices [ including the FAST-1 ] has gained a clear upper hand in WR testing,
I don't interpret the last paragraph as saying that all three devices have an EQUAL chance of being accepted. It just states that none of the products (SurFast, B.I.G., Jamshidi) have gained a CLEAR upper hand. Different strokes for different units?
I guess we'll just have to wait for the report to come out!
Kind Regards
AK |
